Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.
about
β-arrestin1 at the cross-road of endothelin-1 signaling in cancerThe role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsisEndothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptorThe challenge of targeting metastasis.Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cellsmiR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.Endothelin therapeutics in cancer: Where are we?Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.Macitentan: first global approval.Macitentan: An important addition to the treatment of pulmonary arterial hypertension.Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancerMacitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia.Targeting endothelin-1 receptor/β-arrestin1 network for the treatment of ovarian cancer.hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.Upregulation of Endothelin-1/Endothelin A Receptor Expression Correlates with Heparanase Expression in Ovarian Carcinoma.
P2860
Q26740489-429AB5EA-AD3F-49FD-B1B9-23391DD3749CQ27009064-86CE5B7A-C62F-4896-B933-D1AA0C12847EQ28539394-B49213D6-7330-4A8F-B113-E7CC6F6124BDQ36322825-7BA07236-4FC6-4C12-990E-673502A6B9CEQ36608738-D42A8F65-58E0-4F58-B980-AD0800AA73EAQ36782334-96610D1D-82E8-47CF-A841-10A8A76D7E83Q36902508-C89762B9-FFCA-496C-B282-4D7FABE564D2Q37109600-58D500A7-07DF-4B30-9998-E487A3B92292Q37534587-315252D3-1D16-4D3D-B818-A24C601DE412Q38168144-C380812F-A344-4ECB-8F8F-3D37091519C1Q40259209-24876273-BAC2-4DB2-A264-CF37BB05DBB0Q41636889-56B25EF3-DB84-410C-BFB9-197B66345632Q47147169-21802840-AF1A-4667-84F0-39447233DC85Q48010163-39A816D7-2C5A-46FE-A0F6-4C68F9D7D56DQ50035034-21BD68F0-7FD1-42CF-99AA-420919A709B9Q55210200-157D2FFE-ED81-479E-B573-03C252D84BF3
P2860
Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@ast
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@en
type
label
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@ast
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@en
prefLabel
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@ast
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@en
P2093
P2860
P356
P1476
Antivascular therapy for multi ...... ndothelin receptor antagonist.
@en
P2093
Dominic Fan
Emily Brantley
François Lehembre
Isaiah J Fidler
Jang Seong Kim
Panja Strickner
Seung Wook Kim
Sun-Jin Kim
Urs Regenass
P2860
P356
10.1593/TLO.11286
P577
2012-02-01T00:00:00Z